CURE spoke with experts about what life is like for patients in the survivorship care period :© stock.adobe.com. What is life like for someone after cancer? “Often it’s a series of physical adjustments,” Dr. Kevin Billingsley, surgical oncologist and chief […]
With Cancer in Remission, What Is the New Normal for Patients? Read More »
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized: © Tada Images – stock.adobe.com The Food and Drug Administration (FDA), with Imunon Inc., has finalized the study design for the phase 3 OVATION
Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer Read More »
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory leukemia or lymphoma: © nobeatsoffierce – stock.adobe.com The first patients have been dosed in a phase 2 clinical trial evaluating a new off-the-shelf CAR-T cell
First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes Read More »
Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines, in metastatic urothelial carcinoma: © freshidea – stock.adobe.com. Among patients with metastatic urothelial carcinoma — a form of bladder cancer — treatment with Padcev
Padcev With or Without Keytruda Elicits Responses in Urothelial Cancer Read More »
Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky: © Konstanin Yuganov – stock.adobe.com. As part of his talk during the CURE Educated Patient Breast Cancer
What Patients With Breast Cancer Need to Know About Itovebi Read More »
Findings on golidocitinib with PD-1 antibodies for NSCLC patients progressing on anti-PD-1 therapy will be presented at ELCC 2025 in Paris this month. Among patients with non-small cell lung cancer (NSCLC), treatment with the Janus kinase 1 (JAK1)-only inhibitor golidocitinib
Golidocitinib Plus PD-1 Antibodies Being Explored in Lung Cancer Subset Read More »
Fruzaqla plus sintilimab slowed progression in the second line for locally advanced or metastatic renal cell carcinoma: © Dr_Microbe – stock.adobe.com Among patients with locally advanced or metastatic renal cell carcinoma, Fruzaqla (fruquintinib) in combination with sintilimab has been found
Fruzaqla Plus Sintilimab May Slow Renal Cell Carcinoma Progression Read More »
Darzalex and Revlimid maintenance improves survival following autologous stem cell transplantation in multiple myeloma: © stock.adobe.com. Maintenance treatment with Darzalex (daratumumab) and Revlimid (lenalidomide) resulted in superior outcomes compared with standard-of-care Revlimid alone following autologous stem cell transplantation in patients
Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma Read More »
CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference. At the 42nd Annual Miami Breast Cancer Conference, CURE sat down with Kelly Grosklags, a Minneapolis-based clinical social worker focused on oncology psychotherapy and the
Why It’s Important to Have Hard Conversations in Breast Cancer Care Read More »
Longer treatment with Imbruvica and Venclexta was beneficial for patients with relapsed/refractory CLL, improving response rates and minimizing resistance risks. Among patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), extended lead in-treatment with Imbruvica (ibrutinib) followed by two years of
Longer Imbruvica and Venclexta Treatment May Be Beneficial in R/R CLL Read More »
